Monocytes contribute to the atherosclerotic cap by transformation into fibrocytes

International Angiology

Volumn 27, Issue 2, 2008, Pages 114-123

  Medbury, H J ^a   Tarran, S L S ^a   Guiffre, A K ^a   Williams, M W Y ^a   Lam, T H ^a   Vicaretti, M ^a   Fletcher, J P ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Atherosclerosis; Endarterectomy; Fibrocytes; Monocytes; Smooth muscle

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CALPONIN; CD34 ANTIGEN; COLLAGEN; PROCOLLAGEN; SERUM AMYLOID P; SMOOTHELIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CAROTID ENDARTERECTOMY; CELL DIFFERENTIATION; CELL TRANSFORMATION; CONNECTIVE TISSUE CELL; CONTROLLED STUDY; FIBROCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MONOCYTE; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; STEM CELL;

ANTIGENS, CD; ANTIGENS, CD34; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ATHEROSCLEROSIS; CAROTID STENOSIS; FOAM CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MONOCYTES; PROCOLLAGEN; RETROSPECTIVE STUDIES;

EID: 44849139731     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-71.
2. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993;69:377-81.
3. Braganza DM, Bennett MR. New insights into atherosclerotic plaque rupture. Postgrad Med J 2001;77:94-8.
4. Lutgens E, Gijbels M, Smook M, Heeringa P, Gotwals P, Koteliansky VE et al. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol 2002;22:975-82.
5. Lutgens E, Gorelik L, Daemen MJ, de Muinck ED, Grewal IS, Koteliansky VE et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999;5:1313-6.
6. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.
7. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002;8:403-9.
8. Caplice NM, Bunch TJ, Stalboerger PG, Wang S, Simper D, Miller DV et al. Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation. Proc Natl Acad Sci U S A 2003;100:4754-9.
9. Simper D, Stalboerger PG, Panetta CJ, Wang S, Caplice NM. Smooth muscle progenitor cells in human blood. Circulation 2002;106:1199-204.
10. Sata M. Molecular strategies to treat vascular diseases: circulating vascular progenitor cell as a potential target for prophylactic treatment of atherosclerosis. Circ J 2003;67:983-91.
11. Quan TE, Cowper S, Wu SP, Bockenstedt LK, Bucala R. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol 2004;36:598-606.
12. Mori L, Bellini A, Stacey MA, Schmidt M, Mattoli S. Fibrocytes contribute to the myofibroblast population in wounded skin and originate from the bone marrow. Exp Cell Res 2005;304:81-90.
13. Ebihara Y, Masuya M, Larue AC, Fleming PA, Visconti RP, Minamiguchi H et al. Hematopoietic origins of fibroblasts: II. In vitro studies of fibroblasts, CFU-F, and fibrocytes. Exp Hematol 2006;34:219-29.
14. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 2001;166:7556-62.
15. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994;1:71-81.
16. Schmidt M, Sun G, Stacey MA, Mori L, Mattoli S. Identification of circulating fibrocyte as precursors of bronchial myofibroblasts in asthma. J Immunol 2003;171:380-9.
17. Yang L, Scott PG, Dodd C, Medina A, Jiao H, Shankowsky HA et al. Identification of fibrocytes in postburn hypertrophic scar. Wound Repair Regen 2005;13:398-404.
18. Varcoe RL, Mikhail M, Guiffre AK, Pennings G, Vicaretti M, Hawthorne WJ et al. The role of the fibrocyte in intimal hyperplasia. J Thromb Haemost 2006;4:1125-33.
19. Piling D, Buckley CD, Salmon M, Gomer RH. Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol 2003;171:5537-46.
20. Zhao Y, Glesne D, Huberman E. A human peripheral blood monocyte-derived subset acts as pluripotent stem cells. Proc Natl Acad Sci U S A 2003;100:2426-31.
21. Kuwana M, Okazaki Y, Kodama H, Izumi K, Yasuoka H, Ogawa Y et al. Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J Leukoc Biol 2003;74:833-45.
22. Jabs A, Moncada GA, Nichols CE, Waller EK, Wilcox JN. Peripheral blood mononuclear cells acquire myofibroblast characteristics in granulation tissue. J Vasc Res 2005;42:174-80.
23. Vaage J, Lindblad WJ. Production of collagen type I by mouse peritoneal macrophages. J Leukoc Biol 1990;48:274-80.
24. Vaage J, Harlos JP. Collagen production by macrophages in tumour encapsulation and dormancy. Br J Cancer 1991;63:758-62.
25. Lindblad WJ. Perspective article: collagen expression by novel cell populations in the dermal wound environment. Wound Repair Regen 1998;6:186-93.
26. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996;94:2013-20.
27. Wang JF, Wu Y, Medina A, Scott PG, Tredget EE. The role of fibrocytes in post-burn hypertrophic scarring. In: Bucala R, editor. Fibrocytes: new insights into tissue repair and systemic fibroses. Singapore: World Scientific Publishing Co. Inc.; 2007.
28. McDonald JA, Kelley DG, Broekelmann TJ. Role of fibronectin in collagen deposition: Fab′ to the gelatin-binding domain of fibronectin inhibits both fibronectin and collagen organization in fibroblast extracellular matrix. J Cell Biol 1982;92:485-92.
29. Frid MG, Brunetti JA, Burke DL, Carpenter TC, Davie NJ, Reeves JT et al. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/ macrophage lineage. Am J Pathol 2006;168:659-69.
30. Rong JX, Shapiro M, Trogan E, Fisher EA. Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. Proc Natl Acad Sci U S A 2003;100:13531-6.
31. Andreeva ER, Pugach IM, Orekhov AN. Subendothelial smooth muscle cells of human aorta express macrophage antigen in situ and in vitro. Atherosclerosis. 1997;135:19-27.
32. Burke AP, Kolodgie FD, Farb A, Weber DK, Malcom GT, Smialek J et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 2001;103:934-40.
33. Mallat Z, Gojova A, Marchiol-Fournigault C, Esposito B, Kamate C, Merval R et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 2001;89:930-4.
34. Hao H, Gabbiani G, Camenzind E, Bacchetta M, Virmani R, Bochaton-Piallat ML. Phenotypic modulation of intima and media smooth muscle cells in fatal cases of coronary artery lesion. Arterioscler Thromb Vasc Biol 2006;26:326-32.
35. Quan TE, Cowper SE, Bucala R. The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep 2006;8:145-50.
36. Bentzon JF, Weile C, Sondergaard CS, Hindkjaer J, Kassem M, Falk E. Smooth muscle cells in atherosclerosis originate from the local vessel wall and not circulating progenitor cells in ApoE knockout mice. Arterioscler Thromb Vasc Biol 2006;26:2696-702.
37. Grainger DJ, Byrne CD, Witchell CM, Metcalfe JC. Transforming growth factor beta is sequestered into an inactive pool by lipoproteins. J Lipid Res 1997;38:2344-52.
38. Argmann CA, Van Den Diepstraten CH, Sawyez CG, Edwards JY, Hegele RA, Wolfe BM et al. Transforming growth factor-beta 1 inhibits macrophage cholesteryl ester accumulation induced by native and oxidized VLDL remnants. Arterioscler Thromb Vasc Biol 2001;21:2011-8.
39. Garlichs CD, John S, Schmeisser A, Eskafi S, Stumpf C, Karl M et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 2001;104:2395-400.
40. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001;58:4-43.
41. Schonbeck U, Gerdes N, Varo N, Reynolds RS, Horton DB, Bavendiek U et al. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation 2002;106:2888-93.